Want to see INKT full AI Analyst Report?
INKT Stock Chart & Stats
$14.21
-$0.11(-11.96%)
At close: 4:00 PM EST
$14.21
-$0.11(-11.96%)
Day’s Range― - ―
52-Week Range$8.48 - $76.00
Previous CloseN/A
Volume98.55K
Average Volume (3M)39.56K
Market Cap
$55.05M
Enterprise Value$51.30M
Total Cash (Recent Filing)$9.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Aug 12, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding4,981,899
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio-3.68
Price to Book (P/B)-3.35
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-307.12
Enterprise Value/Ebitda-4.17
Forecast
1Y Price Target
$35.00Price Target Upside146.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Translational & Clinical MomentumConsistent translational and early clinical data across cancer, lung injury and fibrosis strengthen the platform thesis. Durable mechanistic coherence across indications supports broader applicability, reduces single-indication binary risk, and underpins sustained partner and investigator interest.
Randomized ARDS Trial (seamless Phase II/III)A randomized 90‑patient Phase II with a seamless Phase II/III pathway and planned FDA engagement materially improves the development pathway. This design can shorten timelines to registrational evidence and provide clear go/no‑go readouts, lowering long‑term clinical development uncertainty.
Scalable Off-the-shelf ManufacturingA scalable, cryopreserved off‑the‑shelf product that avoids HLA matching and lymphodepletion is structurally advantageous. It reduces per‑patient complexity and cost, improves hospital adoption feasibility in acute settings, and supports commercial and trial scalability over the medium term.
Bears Say
Zero Revenue, Persistent LossesAs a pre‑commercial biotech with no revenue and recurring losses, the company relies on external funding to sustain operations. Negative equity and volatile historical cash flows imply constrained financial flexibility and elevate dilution or partnership dependence risk over the next several quarters.
Modest Cash Balance; Financing RiskWith roughly $9.5M cash and multiple ongoing trials and program needs, financing risk is persistent. Limited runway can force dilutive financings or pause activities, making execution and enrollment timelines vulnerable and increasing dependency on partner/non‑dilutive deals.
ARDS & Clinical Execution RiskARDS is a heterogeneous, high‑mortality indication where prior cell therapies have struggled to show survival benefit. Demonstrating consistent, reproducible outcomes in randomized settings is difficult; this raises durable clinical and regulatory risk for the program and the platform's near‑term value realization.
MiNK Therapeutics News
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $8.48 and its highest was $76.00 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $55.05M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 30 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on May 15, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.57.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -0.6.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 4,981,899 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.57 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.998%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MiNK Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (146.31% Upside)
$35.00 (146.31% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.86%
12-Months-Change
Fundamentals
Return on Equity
76.02%
Trailing 12-Months
Asset Growth
143.17%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
INKT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates strong scientific and early clinical momentum: context-dependent mechanistic data, an unusually long median overall survival signal in refractory gastric cancer (>23 months), initiation of a randomized 90‑patient Phase II ARDS trial with a seamless Phase II/III design, scalable off‑the‑shelf manufacturing, and partnerships that reduce dilution. Offsetting risks include a modest cash balance (~$9.5M), ongoing operating losses, the early-stage nature of much of the efficacy data (investigator trials, translational findings, case reports), and typical ARDS and trial execution risks (biologic heterogeneity, prior failures in cell therapy, logistical/geopolitical complexities). On balance, the highlights (clinical signal, trial initiation, manufacturing readiness, partnerships and planned near‑term readouts) outweigh the lowlights, but execution and financing will be critical over the next 12 months.View all INKT earnings summariesINKT Stock 12 Month Forecast
Average Price Target
$35.00
▲(146.31% Upside)
Technical Analysis
Ownership Overview
4.80% Insiders
1.43% Mutual Funds
0.36% Other Institutional Investors
91.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---